Alcohol-associated liver disease due to harmful alcohol use and non-alcoholic fatty liver
disease associated with metabolic syndrome are the two most common liver diseases
worldwide. Control of respective risk factors is the cornerstone in the long-term management
of these diseases. Furthermore, there are no effective therapies. Both diseases are
characterized by metabolic derangements, thus, the focus of this review is to broaden our
understanding of metabolic targets investigated in non-alcoholic fatty liver disease, and how …